37 related articles for article (PubMed ID: 36801466)
1. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
2. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis.
Palipana AK; Gecili E; Song S; Johnson SR; Szczesniak RD; Gupta N
Chest; 2023 Jun; 163(6):1458-1470. PubMed ID: 36610667
[TBL] [Abstract][Full Text] [Related]
3. Effects of Sirolimus on Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis.
Worthy T; Jones A; Yang BE; Ishiwata-Endo H; Gupta N; Moss J
Chest; 2024 Feb; 165(2):303-306. PubMed ID: 37739031
[No Abstract] [Full Text] [Related]
4. Epidemiology of patients with lymphangioleiomyomatosis: A descriptive study using the national database of health insurance claims and specific health checkups of Japan.
Kimura Y; Jo T; Hashimoto Y; Kumazawa R; Ishimaru M; Matsui H; Yokoyama A; Tanaka G; Yasunaga H
Respir Investig; 2024 May; 62(3):494-502. PubMed ID: 38583226
[TBL] [Abstract][Full Text] [Related]
5. Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet.
Gibbons E; Minor BMN; Hammes SR
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37410387
[TBL] [Abstract][Full Text] [Related]
6. Cell survival pathways targeted in rare lung disease affecting women.
Yang B; Moss J
Sci Adv; 2023 May; 9(19):eadi1215. PubMed ID: 37163598
[TBL] [Abstract][Full Text] [Related]
7. Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells.
Olatoke T; Wagner A; Astrinidis A; Zhang EY; Guo M; Zhang AG; Mattam U; Kopras EJ; Gupta N; Smith EP; Karbowniczek M; Markiewski MM; Wikenheiser-Brokamp KA; Whitsett JA; McCormack FX; Xu Y; Yu JJ
Sci Adv; 2023 May; 9(19):eadf8549. PubMed ID: 37163604
[TBL] [Abstract][Full Text] [Related]
8. The role of moesin in diagnosing and assessing severity of lymphangioleiomyomatosis.
Song X; Cai H; Peng W; Chen K; Abuduxukuer Z; Zeng Y; Zhu G; Lu C; Chen Y; Wang J; Ye L; Jin M
Respir Res; 2024 Jan; 25(1):57. PubMed ID: 38267973
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis: No Longer Ultra-rare.
Gupta N; Johnson SR
Am J Respir Crit Care Med; 2024 Feb; 209(4):358-359. PubMed ID: 38190704
[No Abstract] [Full Text] [Related]
10. A case report of lymphangioleiomyomatosis with retroperitoneal masses in pregnancy.
Zhu Y; Wang C; Ding J; Yang M; Bo Y; Ma M; Hu H; Cheng J; Han L; Wang Y
Front Med (Lausanne); 2023; 10():1313503. PubMed ID: 38188337
[TBL] [Abstract][Full Text] [Related]
11. Lymphangioleiomyomatosis and mTOR inhibitors in real world-a narrative review.
Park S; Lee EJ
J Thorac Dis; 2023 Nov; 15(11):6333-6344. PubMed ID: 38090328
[TBL] [Abstract][Full Text] [Related]
12. Spontaneous Pneumothorax in a Young Female With Lymphangioleiomyomatosis.
Ukponmwan O; Gorantla A; Patel KH; Gabutan E; Zhonghua L; McFarlane SI
Cureus; 2023 Sep; 15(9):e45413. PubMed ID: 37854755
[TBL] [Abstract][Full Text] [Related]
13. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
[TBL] [Abstract][Full Text] [Related]
14. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
[TBL] [Abstract][Full Text] [Related]
17. Emerging biomarkers of lymphangioleiomyomatosis.
Nijmeh J; El-Chemaly S; Henske EP
Expert Rev Respir Med; 2018 Feb; 12(2):95-102. PubMed ID: 29171770
[TBL] [Abstract][Full Text] [Related]
18. Current management of lymphangioleiomyomatosis.
Taillé C; Borie R; Crestani B
Curr Opin Pulm Med; 2011 Sep; 17(5):374-8. PubMed ID: 21760507
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
